SUBSCRIBERS
CCCS invites feedback over merger concerns on PAH deals
Response will help watchdog assess if planned consolidation of two clinical laboratories will reduce competition
Add BT as a preferred source
Fiona Lam
Published Fri, Jun 21, 2019 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
THE Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in its planned merger of two private clinical laboratories.
PAH, a unit of private equity giant TPG Capital Asia, intends to integrate the businesses of the two labs - Innovative Diagnostics and Quest Laboratories - after acquiring them last year.
Copyright SPH Media. All rights reserved.
